In combination with intratumoral delivery of Ad-Flt3L and Ad-TK, however, we found that PC61 administration 24 days after tumor implantation (7 days after treatment) completely suppressed adaptive immune responses against GL26 tumor antigens. This evidence concerns the gene TKT and neoplasm.